ESR1 and breast carcinoma: With regard to HDAC proteins, it is widely documented that HDAC inhibitors inhibit E2 signaling in breast cancer cells by inducing transcriptional repression of ESR1, the ERα-encoding gene, as well as ERα protein degradation (83–88).